Velabs Therapeutics

About:

Velabs Therapeutics is a pioneer in microfluidics-based technologies for functional screening of antibodies.

Website: https://veraxa.de

Description:

Velabs Therapeutics is a pioneer in microfluidics-based technologies for functional screening of antibodies. Their high-throughput screening platform allows for testing millions of correctly paired fully natural IgGs from humans and mice for therapeutic effects, rather than just for binding. Rare functional hits are readily identified, which might be laborious or even impossible using other technologies. Velabs’ antibody screens can thus significantly and competitively shorten pre-clinical development.

Total Funding Amount:

3M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Heidelberg, Baden-Wurttemberg, Germany

Founded Date:

2017-01-01

Contact Email:

info(AT)velabs-therapeutics.com

Founders:

Christine Köhler, Christoph Antz, Christoph Merten, Edward Lemke

Number of Employees:

11-50

Last Funding Date:

2019-06-27

IPO Status:

Private

Industries:

© 2025 bioDAO.ai